Table 3 Description of genotyping results in participants with viral breakthrough (VB)
From: Tenofovir diphosphate in dried blood spots and HIV-1 resistance in South Africa
Genotyping result | n | Median [IQR] VL at genotype in log copies/ml | Median [IQR] time to VB in months | Median [IQR] TFV-DP at VB | Median [IQR] 30Â day EM adherence at VB in % | P value |
|---|---|---|---|---|---|---|
Did not amplify | 10 | 2.0 [1.6;2.7] | 7 [4;8] | 380 [227;611] | 45 [25;59] | 0.035 |
Amplified with no HIV-1 drug resistance mutations in evidence | 3 | 4.3 [3.9;4.7] | 5 [1;10] | 40 [17;94] | 33 [17;38] | Â |
Amplified with HIV-1 drug resistance mutations | 5 | 3.2 [2.6;3.8] | 5 [4;6] | 241 [150;247] | 20 [7;37] | Â |
Genotype missed | 3 | – | 5 | 54 [33;214] | 7 [5;20] |  |
Totals | 21 | – | 5 [4;7] | 241 [53;401] | 33 [13;53] |  |